OpportunityTitle: Phase II Clinical Trials of Novel Therapies for Lung Diseases (U01)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Description: Purpose. This Funding Opportunity Announcement (FOA) issued by the National Heart, Lung, and Blood Institute, National Institutes of Health, solicits grant applications from institutions/organizations to conduct proof-of- concept Phase II clinical trials that test a novel intervention for a lung disease or a cardiopulmonary disorder from sleep that have the potential to significantly change clinical management. In addition, each application must include at least one ancillary study tightly related to the clinical question. Mechanism of Support. This FOA will utilize the NIH cooperative agreement (U01) grant mechanism. Funds Available and Anticipated Number of Awards. The NHLBI intends to commit up to $40,600,000 (total costs) over 4 years. It is anticipated that up to two awards will be made for each of 3 receipt dates for a total of four to six awards.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;